Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/bed0290f-10c3-46eb-9ae3-e4a990955009/

GILD

Gilead Sciences Inc
Chart
129.83 USD
Latest Week 2026-07-10
HealthcareDrug Manufacturers - GeneralLARGE
Snapshot 2026-07-12 · 0.9w · Fresh
0.68
OS Score
29.0%
Value
98.0%
Quality
75.0%
Momentum
9/9
F-Score
0.533
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
7 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
8.2%
◐
Veiled Value
Yes
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
Yes
🌱
GARP
✗
🔄
Shareholder Yield
3.3%
💰
High Yield
✗
🚀
Momentum Leaders
12-1 17%
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
Vol 24%
🏷
Sector Cheapest
✗
🧠
Capital Allocators
CAQ 0.82
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
29.0%ile
P/E
17.5×
P/S
5.4×
P/B
6.9×
E/P
0.0667
FCF Yield
0.065
EBITDA/EV
0.082
SH Yield
0.033
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
81.00000000
/100 — 1=cheapest
VC2 (Trending Value)
76.00000000
/100
VC3 (Buyback)
76.00000000
/100
FCF yield of 6.5% is strong — the business generates significant free cash relative to price.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
98.0%ile
ROE
0.392
ROA
0.164
Net Margin
0.310
Op Margin
0.395
GPA
0.419
D/E
1.40
Current
1.97
F-Score
9/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.035
Earn Growth
0.545
Stability
0.301
lower=better
Accruals
-0.028
lower=better
5yr Consist
Yes
ROE of 39% is exceptional. F-Score of 9/9 indicates strong fundamental improvement across multiple dimensions.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
75.0%ile
6M Return
8.5%
12M Return
21.5%
12-1 Mom
16.8%
Risk-Adj
0.71
Vol 252d
23.5%
Vol 60d
51.6%
↑ Expanding
Max DD 12M
-19.2%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
Near-term vol (52%) is expanding vs long-term (24%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.68
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
10.4%
Sector Quality %ile
99.4%
P/E z-score
-0.21
P/B z-score
-0.01
Sector Avg OS
63.1%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 90.0% 91.0% 99.0%
FBIO Fortress Biotech Inc 99.0% 98.0% 85.0% 90.0%
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 83.0% 95.0%
RIGL Rigel Pharmaceuticals Inc 99.0% 89.0% 93.0% 94.0%
TBPH Theravance Biopharma Inc 99.0% 90.0% 99.0% 88.0%
NUTX Nutex Health Inc 98.0% 89.0% 98.0% 86.0%
INVA Innoviva Inc 98.0% 94.0% 94.0% 75.0%
CGEN Compugen 98.0% 89.0% 96.0% 85.0%
Factor Interactions
Quality Momentum — Expensive
Strong quality (98th) and momentum (75th) but expensive (29th value). Premium priced — watch for mean reversion.
Quality at a Premium
High quality (98th) but expensive (29th value). Upside may be limited without earnings growth.
Volatility Expanding
60-day vol (52%) significantly exceeds 252-day (24%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
C
49.5% avg (7 factors)
Quality
A
82.6% avg (8 factors)
Momentum
C
51.0% avg (4 factors)
Risk
A
77.5% avg (1 factors)
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends6 snapshots
Factor Persistence6 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.680—0—
Value %ile0.290—6—
Quality %ile0.980—6—
Momentum %ile0.750—1—
F-Score9.000—6—
Confidence0.951—6—
Volatility0.235—0—
Value Lens2021-07-13 → 2026-07-12
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
17.49
Earnings Yield (E/P)
0.0667
Price / Sales
5.42
Price / Book
6.85
Price / Cash Flow
14.92
FCF Yield
6.5%
EBITDA / EV
8.2%
Sales Yield (1/P·S)
0.1691
Shareholder Yield
Div + net buyback / mktcap
3.3%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
39.2%
Return on Assets
16.4%
Net Margin
31.0%
Operating Margin
39.5%
Gross Profit / Assets
Novy-Marx GPA
41.9%
Debt / Equity
1.40
Current Ratio
1.97
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.028
External Financing
Net issuance — lower=better
0.034
MomentumPrice trend strength over different horizons
6M Return
8.5%
12M Return
21.5%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
16.8%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.71
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
3.5%
Earnings Growth (YoY)
54.5%
Earnings Stability (CV)
Lower = more stable
0.301
5yr Consistent
EPS up every year for 5 years
Yes
Piotroski F-Score
9
Dividend Yield
2.5%
Buyback Yield
0.8%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
81
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
76
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
76
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
Yes
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity